Dexamethasone offer when supplemental oxygen required
Ontario Health Recommendations for Drug Therapy for Adults with Severe to Critical COVID-19 March 21 2025
Dexamethasone and remdesivir and immunomodulator recommendations for severe and critical disease
BCCDC hospitalized patient treatment algorithm 2025 immunomodulator use in critical disease
Tocilizumab and or baricitinib for life support including high flow oxygen
IDSA COVID-19 guideline dexamethasone recommendations updated 2020 with ongoing hosting
Strong recommendation for critically ill patients
Evidence based sources
RECOVERY trial dexamethasone 6 mg daily up to 10 days mortality benefit in hospitalized COVID-19
NEJM 2021 dexamethasone in hospitalized patients
Remdesivir plus dexamethasone observational evidence of reduced mortality versus dexamethasone alone
Clinical Infectious Diseases 2025 cohort analysis
Tocilizumab trials and meta analyses for severe and critical COVID-19
REMAP CAP and RECOVERY program evidence base summarized in provincial algorithms
CDC and Johns Hopkins public health summaries for updated isolation and post return precautions
Post return precautions for 5 days after resuming activities
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.